elapsed_time: 19s
was_input_captured: True
original_text: |
    PD-L1 expression >= 1% in tumor tissue from any site is required for patients with NSCLC; tumor tissue can be archival if no intercurrent systemic therapy was administered, however if no archival tissue is available or if intercurrent systemic therapy was administered, then a biopsy must be obtained for PD-L1 testing; PD-L1 expression must be obtained via central and/or local testing of PD-L1 Immunohistochemistry (IHC) by any Food and Drug Administration (FDA)-approved assay or an assay performed in a Clinical Laboratory Improvement Act (CLIA)-certified laboratory; PD-L1 expression is not required for patients with melanoma
inclusion: True
